The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Individualizing treatment strategies in cardiac amyloidosis: insights from a network meta-analysis
Adolfo Calderón Fernández, MD, National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ), Mexico City, Mexico, discusses factors that should guide treatment selection in cardiac amyloidosis based on findings from a network meta-analysis. He discusses how different treatments may offer distinct benefits, including improvements in biomarkers, functional outcomes, and mortality, highlighting the need for a personalized approach based on patient phenotype. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
First of all, we have to examine the patient that we have in the consultant and we have to analyze what kind of phenotype our patient has and think about which therapy we can use, vutrisiran to reduce anti-PNP functional biomarkers or tafamidis to reduce the mortality or maybe the other one, patisiran, that has consistent improvement but has less statistical significance compared to the others. So the main point or the main goal here is to define the type of patient that we have and define which therapy will help us to help the patient...
First of all, we have to examine the patient that we have in the consultant and we have to analyze what kind of phenotype our patient has and think about which therapy we can use, vutrisiran to reduce anti-PNP functional biomarkers or tafamidis to reduce the mortality or maybe the other one, patisiran, that has consistent improvement but has less statistical significance compared to the others. So the main point or the main goal here is to define the type of patient that we have and define which therapy will help us to help the patient. That’s the most important thing that we are looking for.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
